

CIRM Funded Clinical Trials

**Phase 1 Clinical Development of IO-202, A First-in-Class Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML**

<b>Disease Area:</b>	Leukemia, Acute Myeloid (AML)
<b>Investigator:</b>	Joseph Woodard
<b>Institution:</b>	Immune-Onc Therapeutics
<b>CIRM Grant:</b>	CLIN2-12149
<b>Award Value:</b>	\$6,000,000
<b>Trial Sponsor:</b>	Immune-Onc Therapeutics
<b>Trial Stage:</b>	Phase 1
<b>Trial Status:</b>	Recruiting
<b>Targeted Enrollment:</b>	44
<b>ClinicalTrials.gov ID:</b>	NCT04372433



Joseph Woodard

**Details:**

Immune-Onc Therapeutics will conduct a clinical trial for patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), both of which are types of blood cancer. AML affects approximately 20,000 people in the United States each year and has a 5-year survival rate of about 25 percent. Anywhere from 15-30 percent of CMML cases eventually progress into AML.

The team will treat AML and CMML patients with an antibody therapy called IO-202 that targets leukemic stem cells. The antibody works by blocking a signal named LILRB4 whose expression is connected with decreased rates of survival in AML patients. The goal is to attain complete cancer remissions and prolonged survival.

**Design:**

Phase 1 Trial

**Goal:**

Determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of IO-202 as monotherapy in patients with AML with monocytic differentiation and CMML refractory to or relapsed after available therapies known to be active in their disease.

Contact Trial Sponsor